A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Inclusion Criteria:

1. Voluntarily participate in the study and signed the ICF;

2. Be willing to and able to act on the trial and the follow up procedures;

3. Male or female, aged 18-80 years;

4. Expected survival ≥ 3 months;

5. ECOG PS score 0 or 1;

6. All participants to be enrolled in cohorts 1-5 must be diagnosed withhistopathologically or cytologically confirmed, unresectable locally advanced ormetastatic NSCLC (stage IIIB//IIIC/IV according to the 8th edition of UICC/AJCC) andnot amendable to curative surgery or radiation as assessed by investigator.

Exclusion Criteria:

1. Histopathologically or cytologically confirmed small cell lung cancer;

2. Received major surgeries and still in recovery within 28 days before the first dose;

3. Received any live vaccine within 28 days prior to the first dose or plan to bevaccinated during the study (except for COVID-19 vaccine);

4. Received immune checkpoint inhibitor (anti-PD-1/PD-L1/CTLA-4 antibody) or otherimmune checkpoint inhibitor treatment within 28 days prior to the first dose, orexperienced prior permanent immunotherapy discontinuation due to immunotoxicity;

5. Participated in other clinical trials and received other investigational anti-tumortherapy within 28 days prior to the first dose;

6. Poor compliance and unable to complete the study procedures as assessed byinvestigator;

7. Have any other medical conditions, abnormal physical examinations or laboratoryexaminations that would be suspected interfere with participation or evaluation ofthe trial or increase the risk to the participant, in view of the investigator.